Use of a morphogen comprising a dimeric protein having an amino acid sequence with at least 70% amino acid homology or at least 60% amino acid identity with residues 330-431 of SEQ ID NO: 2, the amino acids being able to be measured and the homology by the PAM250 matrix method described by Dayhoff et al [Atlas of Protein Sequence and Structure, volume 5, 345-352 (1978)], in the preparation of a medicament for alleviating the symptoms of cancer, wherein the Morphogen inhibits the growth of cancer cells.
展开▼
机译:包含具有与SEQ ID NO:2的残基330-431的氨基酸序列具有至少70%氨基酸同源性或至少60%氨基酸同一性的氨基酸序列的二聚体蛋白的吗啡原的用途,所述氨基酸能够被测量和Dayhoff等人[蛋白质序列和结构图集,第5卷,第345-352页(1978)]中所述的PAM250基质方法的同源性,用于制备减轻癌症症状的药物,其中Morphogen抑制生长癌细胞。
展开▼